1st Edition

Atherosclerosis Treatment and Prevention

Edited By Christian Weber, Oliver Soehnlein Copyright 2013
    492 Pages 19 B/W Illustrations
    by Jenny Stanford Publishing

    In recent years, the understanding of the pathophysiological processes of atherosclerosis, a chronic inflammatory disease of the vessel wall being the leading cause for mortality in industrial countries, has tremendously increased. The feasibility of translating such knowledge to novel therapeutic approaches is currently being explored at various levels. This book highlights advances in atherosclerosis and links these to relevant therapeutic strategies. It compiles and details cutting-edge research in cardiovascular medicine from internationally renowned authors.

    Novel approaches in treatment of atherosclerosis, C Weber & O Soehnlein

    Chemokines as therapeutic targets of atherosclerosis, RR Koenen & C Weber

    MIF antagonism as a therapeutic approach to atherosclerosis. J Bernhagen & A Schober

    Peptide-based vaccination strategies to promote Treg- or antibody-mediated atheroprotection, Z Mallat

    Modulation of prostanoids in the treatment of atherosclerosis, JZ Haeggström

    Stabilization of mast cells for taming vulnerable plaques, GP Shi & P Libby

    HDL, ABC transporters, and cholesterol efflux as therapeutic targets in atherosclerosis, DJ Rader

    Role of selective phospholipase A2 inhibition in the treatment of atherosclerosis, C MacPhee

    Modulation of the rennin-angiotensin system in atherosclerosis, A Daugherty

    Role of matrix metalloproteases as targets for the prevention of atherosclerosis, A Newby

    Probucol-derivates in the treatment of atherosclerosis, R Stocker

    Interference with apoptosis and ER stress in the treatment of atherosclerosis, I Tabas

    MicroRNAs in the pathogenesis and therapy of atherosclerotic vascular disease, A Schober & C Weber

    Neutrophils and their granule proteins in the treatment of atherosclerosis, O Soehnlein & C Weber

    Platelets in the treatment of atherosclerosis, D Lievens & P von Hundelshausen

    Costimulatory molecules in the treatment of atherosclerosis, E Lutgens & N Gerdes


    Christian Weber is Chair and Director of the Institute of Cardiovascular Prevention at the Ludwig-Maximilians University in Munich, Germany. After graduating in medicine and completing his training in internal medicine at Ludwig Maximilians University Munich, Germany, and at Harvard Medical School, Boston, USA, he was appointed Professor of Molecular Cardiology at RWTH Aachen University in 2001 and board-certified in clinical cardiology in 2004. Since 2006, he has had a joint appointment as a Professor at the Cardiovascular Research Institute Maastricht. His group is interested in molecular interactions and pathophysiological functions of chemokines and their receptors, adhesion molecules and immune cell subsets in vascular disease. His clinical interests are focused on the prevention of cardiovascular disease using biomarkers and genetic or cellular diagnostics. He is Fellow of the European Society of Cardiology, Editor-in-Chief of Thrombosis and Haemostasis and co-founder of Carolus Therapeutics.

    Oliver Soehnlein is a group leader at the Institute of Cardiovascular Prevention at the Ludwig-Maximilians University in Munich, Germany. After having received his M.D. in 2004 from the Friedrich-Alexander University of Erlangen, Germany, he continued his research at Karolinska Institutet, Stockholm, Sweden, where he received his Ph.D. in Physiology in 2008. Thereafter, he was recruited to the RWTH Aachen University, Germany and in 2011 to the Ludwig-Maximilians University of Munich where he leads a junior research group focusing on the cellular interplay between myeloid cell subsets in acute and chronic inflammatory conditions.